Supported by an educational grant from Sanofi Genzyme, this program is intended for healthcare providers.
— MultipleSclerosis_CME (@ms_cme) August 2, 2021
3) That being said, MS misdiagnosis occurs frequently! MRI as a diagnostic biomarker for MS is only as good as how carefully it is read and applied! See https://t.co/CAEFwJXPc0.
— MultipleSclerosis_CME (@ms_cme) August 2, 2021
5) The answer is a and d. #MultipleSclerosis lesions are classically described as periventricular white matter changes known as “Dawson’s fingers” . . . pic.twitter.com/Oh7M19eCBc
— MultipleSclerosis_CME (@ms_cme) August 2, 2021
7) True or False: Based on updated McDonald Criteria for the diagnosis of MS, grey matter lesions do not count.
— MultipleSclerosis_CME (@ms_cme) August 2, 2021
‘
9) Grey matter lesions differ from white matter lesions both histopathologically as well as immunologically suggesting variable pathologic expression of the MS disease state.
— MultipleSclerosis_CME (@ms_cme) August 2, 2021
11) So How can MRI be an even BETTER biomarker for MS diagnosis? We’ve long known that MS lesions follow a “peri-venular pattern” but new MRI sequences allow this to be visualized in practice. Enter the Central Vein Sign! pic.twitter.com/rjVzgEfOC4
— MultipleSclerosis_CME (@ms_cme) August 2, 2021
13) Welcome back! We’re talking #MRI and biomarkers in #Multiplesclerosis. I am @RanyAburashed and program chair @skriegermd and I are happy you have joined us for this accredited tweetorial. So what about MRI as a clinical course biomarker in MS?
— MultipleSclerosis_CME (@ms_cme) August 3, 2021
15) The topographical model of MS visualizes lesions in the “shallow end” of CNS reserve as most likely to cause relapses and disability – spinal cord and brainstem lesions in particular. Vigilance for these lesions is important for disease course. pic.twitter.com/dOArryS6ct
— MultipleSclerosis_CME (@ms_cme) August 3, 2021
17) Routine brain MRI should be performed every 6-24 months for patients with relapsing forms of #MultipleSclerosis to evaluate for radiologic progression. AJNR 2016;37:394-401
— MultipleSclerosis_CME (@ms_cme) August 3, 2021
19) Summary: #MRI serves as an essential marker for disease diagnosis, inflammatory activity, localization of lesions, and atrophy which all help paint an individual patients clinical disease course.
— MultipleSclerosis_CME (@ms_cme) August 3, 2021
c. Two clinical attacks with no MS appearing lesions
d. One attack with one MS lesion without dissemination in space or time.— MultipleSclerosis_CME (@ms_cme) August 3, 2021
22) Welcome back! The answer to yesterday’s quiz was B: two clinical attacks with two MS-appearing lesions. I'm @RanyAburashed. Encourage your colleagues, fellows, and residents to follow us here at @ms_CME for serialized Twitter-based accredited education!
— MultipleSclerosis_CME (@ms_cme) August 4, 2021
24) Neurofilament Light may serve as a nonspecific but quantitative marker of axonal and neuronal injury in patients with multiple sclerosis (https://t.co/6BlRCnKoRJ).
— MultipleSclerosis_CME (@ms_cme) August 4, 2021
26) Recent advances in ELISA assays using Single Molecule Array Assays (SIMOA) have led to the potential utility of measuring Neurofilaments in biofluid with high correlation to CSF . . .
— MultipleSclerosis_CME (@ms_cme) August 4, 2021
28) Elevated neurofilament light levels most likely represent which of the following?
a. Clinical relapse or disease activity
b. MS subtype
c. Cognitive decline
d. DMT optimal response— MultipleSclerosis_CME (@ms_cme) August 4, 2021
30) GFAP is another important potential marker for disease monitoring/prognostication. It is an astrocytic cytoskeletal protein that is highly expressed in astrogliosis in MS lesions.
— MultipleSclerosis_CME (@ms_cme) August 4, 2021
32) Chitinase 3-Like 1 or CHI3L1 is a glycoprotein expressed in activated glia, activated macrophages, and vascular smooth muscle. It is overexpressed in patients with CIS who convert to cdMS and is also correlated with GAD enhancing lesions on MRI.
— MultipleSclerosis_CME (@ms_cme) August 4, 2021
34) Summary: MS prognosis remains difficult to predict on an individual basis! Emerging individual serum biomarkers or a collection of bioprofiles may help in earlier detection of disease progression,
— MultipleSclerosis_CME (@ms_cme) August 4, 2021
36) That's it! You made it! Free CE/#CME! Now go to https://t.co/epzCXGoRpL and claim your credit! I am @RanyAburashed. Follow @MS_CME for more tweetorials, and visit us at https://t.co/rUou3c5Z2j and . . . pic.twitter.com/2ubHe6aBWX
— MultipleSclerosis_CME (@ms_cme) August 4, 2021
37) . . . at https://t.co/B00BrmcAUi and https://t.co/lwK5CUCmLU for unrolled programs where credit opportunity is still active! #neurotwitter #MSTwitter. Thanks to @SKriegerMD for chairing this important and innovative program!
— MultipleSclerosis_CME (@ms_cme) August 4, 2021
